Recent research has linked inflammation, caused by increased fat tissue, with insulin resistance. In type 1 diabetes, the immune system attacks the cells that make insulin. As circulating pro-inflammatory messengers and macrophages increase, insulin resistance follows. While other factors can contribute to insulin resistance and diabetes, the link between chronic inflammation caused by obesity and diabetes is very strong.
The infiltration of macrophages into fat tissue and their subsequent release of pro-inflammatory cytokines into circulation occur at a greater rate in type II diabetics than in non-diabetics (Pickup et al. 2000, Nappo et al. 2002, Ortega Martinez de Victoria et al. 2009). Pro-inflammatory cytokines clearly decrease insulin sensitivity (Bastard et al. 2006).
“One possible explanation for this is the imbalance between two types of immune cells, T-helper 1 cells and T-helper 2 cells. In children with diabetes, the balance tends to favor T-helper 1 cells; in those with asthma, T-helper 2 cells. It’s difficult for one child to have both.”
Type II diabetes is also linked to inflammation, as chronic inflammation releases TNF (tumor necrosis factor), which makes cells more resistant to insulin. “No one would have thought these things were related, but they are” says Dr. Walter Willett, chairman of the department of nutrition at the Harvard School of Public Health.
We believe Infeperium breakthrough therapies to be a new category of drug that may be characterized as a Biological Response Modifier and an “Immunomodulator.” We believe that many disease pathologies that affect individuals are the result of an over-active immune system. Specifically, when a viral agent begins to adversely affect an individual’s cells, the immune system frequently becomes overactive, which destroys the viral agent but also injures surrounding healthy cell structures. We believe other disease pathologies suppress an individual’s immune system, which allows other diseases and agents to kill healthy cells.
Although research is always ongoing, the product in its present form is complete. Research has concluded that Infeperium breakthrough therapies regulate the bodies immune system to prevent it from both over-reacting and under-reacting to a viral invasion of an individual’s body systems. We believe that Infeperium breakthrough therapies contains a number of unique peptide or lipopeptide molecules which may neutralize viral pathogens and their inhibitory properties by activation of a cytokine system. This, in turn, will enhance an individual’s cell mediated immunity and augment the individual’s humoral immune system possibly by eliminating negative inhibitory cytokine factors and pathogenic free-floating organisms, while simultaneously sparing normal and healthy cells.
Preserving Acute inflammation which is necessary for healing, restoration and defense against invading pathogens.Reducing Chronic inflammation which is the beginning of the reversal of degenerative disease.
II. Restores proper Cell Signaling
Through cytokines, cell messenger pathways, cellular communication and transduction.Reverses aberrant, dysregulated, disrupted, error altered, confused and distracted communication.
III. Acts as an Adjuvants or Adjunct
Help regulate and restore the proper on/off switches of immune cascade proteins and cell activity, especially Apoptosis (programmed cell death).This will amplified proper cell activity, messaging and signal routing.
Infeperium is only available for treatment in Mexico.